



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.2977511>Available online at: <http://www.iajps.com>

Research Article

**IN-VITRO COMPARATIVE STUDY OF THREE DIFFERENT BRANDS OF FAMOTIDINE 40 MG TABLETS AVAILABLE IN LOCAL PHARMACIES OF KARACHI**Samina ALAM<sup>1</sup>, Huma DILSHAD<sup>1</sup>, Halima MOIN<sup>1</sup>, Ghazala PARVEEN<sup>1</sup>, Dr. Tanweer ALAM<sup>2</sup>, Ghulam SARWAR<sup>1</sup><sup>1</sup>Faculty of Pharmacy, Jinnah University for women, Karachi. 5C-Nazimabad, 74600.<sup>2</sup>Dean, Faculty of Pharmacy, Iqra University, Karachi.

Article Received: March 2019

Accepted: April 2019

Published: May 2019

**Abstract:**

*Famotidine 40 mg film coated tablet by invitro comparative study, together with the official and non official compendial test. Famotidine is an aggressive inhibitor of histamine H2-receptors. The pivotal clinically critical pharmacologic activity of Famotidine is to hold of gastric discharge. Both the acid concentration and volume of gastric secretion are concealed by famotidine, while changes in pepsin discharge are relative to volume generation. Famotidine is more potent than other class of drugs like the drug is intended to release after oral administration for immediate release so we execute testing analysis to illustrate the procedure, the major test for analyzing the effectiveness of drug comprises, dissolution, assay, disintegration time, thickness and weight variation in three brands available in market of Karachi Pakistan. The weight variation test shows outcomes within the limits and all brands dissolves within 30 minutes, every brand showed the drug dissolution more than 75 % within the 30 minutes, all outcome showed good effectiveness and producing outcomes within the limits and complying the USP recommendation.*

**Key Words:** *Compendial test, immediate release, competitive inhibitor, famotidine, tablets***Corresponding author:****Samina ALAM,**

Faculty of Pharmacy, Jinnah University for women, Karachi

5C-Nazimabad, 74600. Email: saminaalam@gmail.com

QR code



Please cite this article in press Samina ALAM et al., *In-Vitro Comparative Study of Three Different Brands of Famotidine 40 Mg Tablets Available in Local Pharmacies of Karachi.*, Indo Am. J. P. Sci, 2019; 06(05).

**INTRODUCTION:**

Famotidine was developed by Yamanouchi Pharmaceutical Co(1) It was licensed in the mid-80s by Merck & Co(2) and is marketed by a organization between Merck and Johnson & Johnson. The imidazole ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 9 times extra strong than ranitidine, and 32 times more potent than cimetidine.(3) .Famotidine is a viable histamine H<sub>2</sub>-receptor antagonist. Its main pharmacodynamic effect in humans is inhibition of gastric acid secretion (4) Famotidine is the most dominant, specific H<sub>2</sub>-receptor opponent yet existing for ulcer treatment. On a power premise, famotidine is roughly multiple times more viable than ranitidine and multiple times more compelling than cimetidine. Moreover, it expands the gastric mucosal blood stream, bringing about an expanded haemostatic impact.(5) Famotidine is N'-(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide.

The molecular formula of famotidine is C<sub>8</sub>H<sub>15</sub>N<sub>7</sub>O<sub>2</sub>S<sub>3</sub> and its molecular weight is 337.45. Famotidine is freely soluble in glacial acetic acid, it is a white to pale yellow crystalline compound, slightly soluble in methanol, soluble in water very faintly, and almost insoluble in ethanol(6) Different techniques have been accounted for assessment of famotidine, which comprise of spectrophotometric strategies, spectrophotometric and spectrofluorimetric strategy and investigation by stream infusion .In the present correspondence, a basic spectrophotometric strategy has been made for the evaluation of famotidine from pharmaceutical arrangements (7) For invitro study dissolution tests important they have to advocate in vivo study situation The use of phosphate buffers which do not recount to gastrointestinal luminal fluids may elucidate the summary in vitro-in vivo correlations obtained for modified release dosage forms(8) It has been uncovered that expanding ionic quality and cradle limit of disintegration media builds prescription discharge rate.(8) catogries in a few pharmaceutical industry, tablet disintegration examination is distinctively used to give genuine in vitro medication discharge data for both quality control purposes, i.e., solid measurement structure to evaluate group to-bunch consistency, for example, tablets, and medication advancement, i.e., to conjecture profiles fortress in vivo medication discharge . (9)(10) For immediate release tablets, The drug is proposed to be discharged quickly after administration or the tablet is disintegrated in fluid before admission and consequently regulated as solution(10) Generally the more noteworthy the

weight connected the harder the tablet., although the attributes of granulation have additionally bearing hardness .a tablet durability might be resolved using friabilator. For the restorative specialist in the tablet to turn out to be completely accessible for retention the tablet should initially break down and release the medication into the body liquid for disintegration the amount fill in the die determine the heaviness of the tablet the volume of fill is changed in accordance with the initial few of tablets to yield the ideal weight and steady. (11)

**Instruments:**

Following are the instruments used for analysis of all three brands of famotidine 40 mg tablet. Electronic balance FX 400, Vernier caliper (VC-TY56), Disintegration tester 121-L Galvano scientific, GDT-7L Galvano scientific dissolution tester, p H meter (GH-09) and UV – Visible spectrophotometer Shimadzu (1800)

**MATERIALS AND METHODS:**

For the comparative study of famotidine 40 mg tablet, Jinnah university for women ,provided the opportunity to conduct the pharmacopeial test, included weight variation test ,disintegration time test ,assay ,thickness and dissolution test at their research lab. All brands were purchased from different pharmacies available in Karachi and all the reagents were provided by Deajung chemical Korea.

**Weight Variation Test.** Most of the pharmacopeia include a simple weight test on a specified number of tablets, individual weight and the arithmatic mean were calculated. The permitted limit of weight variation in USP not more than 2 tablets differ from the mean by more than 5% and in B.P the permitted limit of weight variation are essentially the same as that of the USP. For performing weight variation test select 20 tablets of famotidine 40 mg and each tablet weight were recorded in mg, average weight were also noted by using electronic balance.

**Thickness Test.** The thickness test is nonofficial test and it could be considered as an additional control to tablet dimension and it increase reproducibility. Calibrated vernier caliper were used to determined the thickness of the tablets. Adjusting the ten individual tablets, sandwiched between the jaw of vernier caliper, record the thickness results in mm.

**Disintegration Time.** The disintegration test is useful as a quality assurance tool for conventional dosage forms. The disintegration test is carried out by using disintegration tester which was consist of a basket rack holding 6 tubes, open at the top and

bottom, the bottom of the tube was covered by 40 mesh screen, the basket was immersed in a bath of suitable liquid held at 37 °C preferably in a 1 liter beaker. By using disintegration tester 6 tablets were placed in tubes containing baskets and cover it with discs and disintegration time were determined by visualizing each tablet to break and completely dissolved, showing the time in sec or minutes.

**Pharmaceutical Assay.** Spectrophotometer is suitable for measuring the ultraviolet and visible range of the spectrum. Following are analytical testing method of the famotidine 40 mg tablet by UV-Visible spectrophotometer 1800 UV-VIS (shimadzu).

#### **Diluent Preparation**

Methanol : 400 ml

Distilled water : 600 ml

Phosphoric acid : 2 ml

Mixed the above solution and adjusted pH to 5.0 either by NaOH or by Phosphoric acid.

#### **Standard Preparation**

$$\frac{A_{sp} \times S_w \times 2 \times 50 \times 100 \times P}{A_{std} \times 50 \times 100 \times Sp.wt. \times 2} = \% \text{ Avg. wt} = \text{mg/tab.}$$

Where,

- Asp = Absorbance due to Famotidine in sample preparation.  
 Astd = Absorbance due to Famotidine in standard preparation.  
 Sw = Standard weight.  
 Sp.wt. = Sample weight.  
 P = Purity of standard.

**Dissolution Test.** Dissolution tester GDT-7L Galvano scientific used for the comparative study of famotidine 40 mg tablet. Tablet dissolution is a standardized method for measuring the rate of drug release from a dosage form. The principle function of

Weigh accurately 0.0500 gm of Famotidine standard in 50 ml volumetric flask. Dissolved in diluent and made up the volume with diluent. Dilute 2 ml of the above solution to 100ml volumetric flask and filled up the volume with diluent and shaken well.

#### **Sample Preparation**

Accurately weighed the 20 tablets powder equivalent to Famotidine standard and shift into 50 ml volumetric flask include about 30 ml of diluent and sonicate for about 30 minutes. After 30 minutes made up the volume with diluent and shaken well. Filtered the above solution through whatman # 1 filter paper. Dilute 2 ml of the above filtrate to 100 ml volumetric flask and filled up the volume with diluent and shaken well. Measured the absorbance of both standard and sample preparation on a suitable spectrophotometer at 265 nm using diluent as blank.

#### **Calculations**

Calculate the content of Famotidine per tablet by using following equation.

the dissolution test is to optimization of therapeutic effectiveness during product development and stability assessment and routine assessment of production quality to ensure uniformity between products lots.

#### **Dissolution Condition**

|           |                 |
|-----------|-----------------|
| APPARATUS | USP II (PADDLE) |
| RPM       | 50              |
| TIME      | 30 MINUTES      |
| LIMIT     | NLT 75 %        |

#### **Dissolution Medium**

pH 4.5, 0.1M potassium phosphate buffer. Prepared by dissolving 13.6 gm of monobasic potassium phosphate (Potassium dihydrogen phosphate) in one liter of water.

#### **Standard Preparation**

Weigh accurately 0.0440 g of Famotidine standard in 100 ml of volumetric flask and dissolved in dissolution medium. Pipette 10ml of the above solution into 100 ml volumetric flask and dilute the volume with dissolution medium and shaken well.

**Sample Preparation**

Place one tablet each in 6 dissolution flask containing 900 ml of dissolution medium, previously adjusted to  $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$ . Immediately operate the apparatus. At the specified time, withdraw the sample from a zone midway after min,30 min between the surface of medium and top of the rotating blade not less than 1 cm from vessel wall. Filtered the sample, evaluated the absorbance of standard and sample preparation on a appropriate spectrophotometer at the wavelength of 265 nm using dissolution medium as a blank. Calculated the amount of Famotidine dissolved in specified time by using following equation.

$$\frac{\text{Asp} \times \text{Sw} \times 10 \times 900 \times \text{P}}{\text{Astd} \times 100 \times 100 \times \text{Sp}} = \% \text{ dissolved.}$$

Where,

- Asp = Absorbance of sample due to famotidine.  
 Astd = Absorbance of standard due to famotidine.  
 Sw = Standard weight.  
 Sp = Tablet sample.  
 P = Purity of standard.

**RESULTS:**

The comparative study of Famotidine 40 mg Tablet showed all the results within the limits and following USP. Physicochemical analysis of three different brands of Famotidine 40 mg tablet followed the weight variation test, disintegration test ,thickness ,diameter, dissolution on single point and assay. Results of weight variation/average weight for Fam-01 was 234.2 mg with (260.127 – 208.272 mg) upper and lower limits,for Fam -2 average weight was 309.5 mg with (356.9 – 262.09 mg) upper and lower limits,for Fam -3 average weight was 201.7 mg with(231.077-172.323mg) upper and lower limits shown in table 02.The results of thickness variation(mm) of Fam- 01 was 4.17 mm with(4.3 – 3.9mm ) upper and lower limits, Fam-02 was 4.7 mm with (4.8 – 4.5 mm) upper and lower limits, Fam – 03 was 4.25 mm with (4.85 – 4.01 mm) upper and lower limits shown in table 03. The results of diameter variation of Fam – 01 was 8.83 mm with (9.0 – 8.58 mm) upper and lower limits, Fam – 02 was 9.35 mm with (9.9 – 8.7 mm ) upper and lower limits, Fam –

03 was 8.7 mm with (8.89 – 8.50 mm) upper and lower limits shown in table 04.The disintegration test showing results for Fam – 01 was 3 minutes, Fam-02 is 5 minutes,Fam – 03 was 5 minutes with the BP/USP limit(NMT 30 minutes) shown in table 05, The Dissolution test showing the results within the limits. Results for Fam – 01 was 98 %, Fam – 02 was 104.5 %, Fam – 03 is 99.23 % with USP limit NLT 75 % shown in table 6, The results for Assay percent test for Fam -01 is 99.41 % ,Fam-02 was 99.42 % and Fam -03 was 98.08 % with USP limit (90 – 110 %) shown in table 7..

**DISCUSSION:**

The main objective of this research work was to evaluate and compared the effectiveness of the three different brands of famotidine 40 mg tablet available in local markets of Karachi. According to the BP/USP limits evaluation of physical and chemical test like weight variation test ,thickness, diameter disintegration ,dissolution and assay percent test were showing results within their specified upper and lower limit of 7.5%.There is no official limits of thickness and diameter but all brands of famotidine 40 mg tablet were having similar thickness and diameter within the brands. And disintegration time were also found within the limits of BP/USP , brand Fam-01 were dissolved within 3 minutes as compare to the other brands which were took 5 minutes to dissolved.US Pharmacopeial limits of dissolution test is NLT 75 % in 30 minutes and all brands of famotidine 40 mg tablet dissolved within time but Fam - 02 have shown the excellent results as compared to other brands. assay percent limits of famotidine 40 mg tablet according to the USP have 90 – 110% and all brands were found within the limits.

**CONCLUSION:**

It was concluded from the results of famotidine 40 mg tablet that all brands showing minor variation in there invitro quality control test but these variation were found under the specified limits of USP/BP, so quality standards of all three brands are same but there is a difference in there packaging and there MRP's.

**Table 1 : Specifications of famotidine tablets 40 mg different Brands**

| NO | Brand Name | Serial number | Code Number | Batch number |
|----|------------|---------------|-------------|--------------|
| 1  | Nocid      | Fam-1         | 018064      | J0022        |
| 2  | Bessfam    | Fam-2         | 047460      | 009          |
| 3  | Famosure   | Fam-3         | 029249      | 025          |

**Table 2 : Statistical weight Variation test of famotidine tablets 40 mg**

| No | Serial number | Batch number | Average weight (x)mg U.S.P | Standard deviation (S) | Upper Limit U.S.P (UCL=X+ 7.5 S) | Lower Limit U.S.P (LCL=X+-7.5 S) |
|----|---------------|--------------|----------------------------|------------------------|----------------------------------|----------------------------------|
| 1  | Fam-1         | J0022        | 234.2                      | 3.457                  | 260.127                          | 208.272                          |
| 2  | Fam-2         | 009          | 309.5                      | 6.321                  | 356.9                            | 262.092                          |
| 3  | Fam-3         | 025          | 201.7                      | 3.917                  | 231.077                          | 172.323                          |

**Table :3 Statistical thickness Variation test of famotidine tablets 40 mg**

| No | Serial number | Batch number | Average thickness (mm) | Standard deviation (S) | Upper Limit (UCL=X+ 3S) | Lower Limit (LCL=X+- 3 S) |
|----|---------------|--------------|------------------------|------------------------|-------------------------|---------------------------|
| 1  | Fam-1         | J0022        | 4.17                   | 0.068                  | 4.374                   | 3.966                     |
| 2  | Fam-2         | 009          | 4.7                    | 0.048                  | 4.844                   | 4.556                     |
| 3  | Fam-3         | 025          | 4.25                   | 0.078                  | 4.484                   | 4.016                     |

**Table :4 Statistical diameter Variation test of famotidine tablets 40 mg**

| No | Serial number | Batch number | Average diameter (mm) | Standard deviation (S) | Upper Limit (UCL=X+ 3S) | Lower Limit (LCL=X+- 3 S) |
|----|---------------|--------------|-----------------------|------------------------|-------------------------|---------------------------|
| 1  | Fam-1         | J0022        | 8.83                  | 0.0823                 | 9.076                   | 8.581                     |
| 2  | Fam-2         | 009          | 9.35                  | 0.187                  | 9.911                   | 8.789                     |
| 3  | Fam-3         | 025          | 8.7                   | 0.066                  | 8.898                   | 8.502                     |

Table :5 Disintegration test of famotidine tablets 40 mg

| Serial number | Code Number | Batch number | Disintegration Time Result (min) | B.P/USP Spec. | Deviation From BP/USP |
|---------------|-------------|--------------|----------------------------------|---------------|-----------------------|
| Fam-1         | 018064      | J0022        | 3 min                            | NMT 30 min    | Pass                  |
| Fam-2         | 047460      | 009          | 5 min                            | NMT 30 min    | Pass                  |
| Fam-3         | 029249      | 025          | 5 min                            | NMT 30 min    | Pass                  |

Table :6 Dissolution test of famotidine tablets 40 mg

| Serial number | Code Number | Batch number | Dissolution test Result (%) | USP Spec. | Deviation From Official limit |
|---------------|-------------|--------------|-----------------------------|-----------|-------------------------------|
| Fam-1         | 018064      | J0022        | 98.0                        | NLT 75%   | Pass                          |
| Fam-2         | 047460      | 009          | 104.5                       | NLT 75%   | Pass                          |
| Fam-3         | 029249      | 025          | 99.23                       | NLT 75%   | Pass                          |

Table :7 Assay percent test of famotidine tablets 40 mg

| Serial number | Code Number | Batch number | Assay percent test Result (%) | USP Spec. | Deviation From Official limit |
|---------------|-------------|--------------|-------------------------------|-----------|-------------------------------|
| Fam-1         | 018064      | J0022        | 99.41                         | 90 -110%  | Pass                          |
| Fam-2         | 047460      | 009          | 99.42                         | 90 -110%  | Pass                          |
| Fam-3         | 029249      | 025          | 98.98                         | 90 -110%  | Pass                          |

**REFERENCES:**

- Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR. Disposition of famotidine in renal insufficiency.(1987).*The J of Clinical Pharmacology*, .(1987). 27(10), 782-787.
- Khan S, Qamar F, Zafar F, Ali H, Naveed S, Sarwer G, Usmanghani K, Alam MT, Khan A. Analysis of Famotidine in API and Formulation using UV and HPLC. *RADS JPPS*(2017) ;5(1):50-4.
- Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H<sub>2</sub>-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. *Gastroenterology*. 1985 Apr 1;88(4):1026-33.
- Goenka MK, Kochhar R, Chakrabarti A, Kumar A, Gupta O, Talwar P, Mehta SK. Candida overgrowth after treatment of duodenal ulcer: A comparison of cimetidine, famotidine, and omeprazole. *J of clinical gastroenterology*. 1996 Jul 1;23(1):7-10.
- Seifert R, Wenzel-Seifert K, Bürckstümmer T, Pertz HH, Schunack W, Dove S, Buschauer A, Elz S. Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H<sub>1</sub>-receptor. *J of Pharmacology and Experimental Therapeutics*. 2003 Jun 1;305(3):1104-15
- Shoaib MH, Siddiqi SA, Yousuf RI, Zaheer K, Hanif M, Rehana S, Jabeen S. Development and

- evaluation of hydrophilic colloid matrix of famotidine tablets. *Aaps Pharmscitech*. 2010 Jun 1;11(2):708-18.
7. Wang Y, Armenante PM. A novel off-center paddle impeller (OPI) dissolution testing system for reproducible dissolution testing of solid dosage forms. *J of pharmaceutical sci*. 2012 Feb 1;101(2):746-60.
  8. Fadda HM, Basit AW. Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. *J of drug delivery sci and technology*. 2005 Jan 1;15(4):273-9.
  9. Bai G, Wang Y, Armenante PM. Velocity profiles and shear strain rate variability in the USP Dissolution Testing Apparatus 2 at different impeller agitation speeds. *Int J.of pharmaceutics*. 2011 Jan 17;403(1-2):1-4.
  10. Hwang KM, Kim SY, Nguyen TT, Cho CH, Park ES. Use of roller compaction and fines recycling process in the preparation of erlotinib hydrochloride tablets. *Eur J of Pharmaceutical Sci*. 2019 Apr 1;131:99-110..
  11. Allen, L., & Ansel, H. C. (2013). *Ansel's pharmaceutical dosage forms and drug delivery systems*. Lippincott Williams & Wilkins.